HK1219224A1 - 角結膜病症的治療劑 - Google Patents

角結膜病症的治療劑

Info

Publication number: HK1219224A1
Authority: HK; Hong Kong
Prior art keywords: therapeutic agent; keratoconjunctive disorders; keratoconjunctive; disorders; therapeutic
Prior art date: 2012-11-08

Application number

HK16107218.3A

Other languages

English (en)

Inventor

木村和博

Original Assignee

Univ Yamaguchi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-08

Filing date

2016-06-22

Publication date

2017-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50684334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219224(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-22 Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi

2017-03-31 Publication of HK1219224A1 publication Critical patent/HK1219224A1/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Dermatology (AREA)

HK16107218.3A 2012-11-08 2016-06-22 角結膜病症的治療劑 HK1219224A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2012246373		2012-11-08
PCT/JP2013/006563 WO2014073209A1 (ja)	2012-11-08	2013-11-07	角結膜障害の治療剤

Publications (1)

Publication Number	Publication Date
HK1219224A1 true HK1219224A1 (zh)	2017-03-31

Family

ID=50684334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK16107218.3A HK1219224A1 (zh)	2012-11-08	2016-06-22	角結膜病症的治療劑

Country Status (17)

Country	Link
US (6)	US9492431B2 (zh)
EP (1)	EP2918290B1 (zh)
JP (3)	JP6254529B2 (zh)
KR (1)	KR102173932B1 (zh)
CN (2)	CN105188753B (zh)
AU (2)	AU2013342882B2 (zh)
BR (1)	BR112015010428B1 (zh)
CA (1)	CA2890424C (zh)
CL (2)	CL2015001225A1 (zh)
ES (1)	ES2834111T3 (zh)
HK (1)	HK1219224A1 (zh)
MX (2)	MX363111B (zh)
NZ (1)	NZ708756A (zh)
RU (1)	RU2659203C2 (zh)
SG (2)	SG10201704687YA (zh)
WO (1)	WO2014073209A1 (zh)
ZA (1)	ZA201504065B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2890424C (en)	2012-11-08	2020-11-17	Yamaguchi University	Therapeutic agent for keratoconjunctive disorders
EP2740485B1 (en) *	2012-12-07	2018-10-31	Brightpulse Holding LTD.	Protein slurp-1 for use in the treatment of ocular diseases
EP3000466B1 (en)	2013-05-22	2018-08-15	Yamaguchi University	Inhibitor for retinochoroidal disorders
BR112018075422A2 (pt)	2016-06-08	2019-03-12	Clementia Pharmaceuticals Inc.	métodos para tratar ossificação heterotópica
KR20190100187A (ko)	2016-11-16	2019-08-28	클레멘티아 파마슈티컬즈, 인크.	다중 골연골종(mo)을 치료하는 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT678086E (pt)	1993-01-11	2000-05-31	Ligand Pharm Inc	Compostos com selectividade para receptores de retinoides x
US5824685A (en)	1995-02-01	1998-10-20	The Johns Hopkins University School Of Medicine	Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) *	1995-06-06	1997-04-29	Bristol-Myers Squibb Company	Rary-specific retinobenzoic acid derivatives
US5919970A (en)	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en)	1997-07-14	2009-04-07	Osiris Therapeutics, Inc.	Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) *	1999-03-08	2001-03-20	The University Of Mississippi	1,2-dithiolane derivatives
US6313168B1 (en)	1999-12-15	2001-11-06	Allergan Sales, Inc.	Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en)	1999-12-15	2003-06-19	Maurizio Pacifici	Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
EP1265637A2 (en)	2000-03-14	2002-12-18	The University Of Western Ontario	Compositions and methods for affecting osteogenesis
MXPA03002861A (es)	2000-10-02	2003-07-14	Hoffmann La Roche	Nuevos retinoides para tratamiento del enfisema.
BR0212583A (pt)	2001-09-18	2004-10-13	Hoffmann La Roche	Agonistas i para retinóides de alquil uréia
ATE427929T1 (de)	2001-09-18	2009-04-15	Hoffmann La Roche	Substituierte harnstoff retinoid agonisten ii
AUPR892501A0 (en)	2001-11-16	2001-12-13	Peter Maccallum Cancer Institute, The	Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en)	2002-08-28	2005-05-12	Reading Christopher L.	Therapeutic treatment methods 2
JP2005206544A (ja)	2004-01-23	2005-08-04	Yasuyoshi Uchida	筋肉再生剤
AU2005240078A1 (en)	2004-04-30	2005-11-17	Allergan, Inc.	Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
JP2008533165A (ja)	2005-03-17	2008-08-21	エランファーマインターナショナルリミティド	ナノ粒子免疫抑制性化合物の注射可能組成物
US7345931B2 (en)	2005-08-01	2008-03-18	Infineon Technologies Ag	Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
CN101316584A (zh)	2005-09-27	2008-12-03	北海道公立大学法人札幌医科大学	用于预防及治疗由血管通透性亢进引起的眼病的医药
KR101026652B1 (ko)	2006-03-31	2011-04-04	에프. 호프만-라 로슈 아게	레티노이드 화합물의 제조 방법
ES2702128T3 (es)	2006-05-16	2019-02-27	Io Therapeutics Llc	Antagonista o agonista inverso de RAR para uso en el tratamiento de efectos secundarios de quimioterapia y/o terapia de radiación
US8444970B2 (en) *	2006-10-27	2013-05-21	Lpath, Inc.	Compositions and methods for treating ocular diseases and conditions
WO2008063842A2 (en)	2006-11-02	2008-05-29	Aestus Therapeutics, Inc.	Methods of treating neuropathic pain with agonists of ppar-gamma
US9119777B2 (en)	2008-05-30	2015-09-01	Microdose Therapeutx, Inc.	Methods and compositions for administration of oxybutynin
JP2009235031A (ja) *	2008-03-28	2009-10-15	Nano Egg:Kk	角膜組織の再生促進剤
EP2379174A4 (en)	2008-12-18	2012-11-14	Astrazeneca Ab	PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
EP2393915A4 (en)	2009-02-05	2012-12-26	Regenertech Pty Ltd	PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
MX361414B (es) *	2010-09-01	2018-12-05	Univ Jefferson	Composición y método para reparación y regeneración muscular.
EP2621588A4 (en)	2010-09-27	2014-09-03	Microdose Therapeutx Inc	METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
US10485780B2 (en)	2011-03-14	2019-11-26	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en)	2011-03-24	2012-09-27	The Scripps Research Institute	Compounds and methods for inducing chondrogenesis
US8772273B2 (en)	2011-10-04	2014-07-08	Quretino Therapeutics, Inc.	Formulations and uses of retinoic acid receptor selective agonists
CA2890424C (en) *	2012-11-08	2020-11-17	Yamaguchi University	Therapeutic agent for keratoconjunctive disorders
EP3000466B1 (en)	2013-05-22	2018-08-15	Yamaguchi University	Inhibitor for retinochoroidal disorders

2013
- 2013-11-07 CA CA2890424A patent/CA2890424C/en active Active
- 2013-11-07 ES ES13854101T patent/ES2834111T3/es active Active
- 2013-11-07 CN CN201380069723.0A patent/CN105188753B/zh active Active
- 2013-11-07 RU RU2015121628A patent/RU2659203C2/ru active
- 2013-11-07 CN CN201811479227.3A patent/CN109589324B/zh active Active
- 2013-11-07 EP EP13854101.6A patent/EP2918290B1/en active Active
- 2013-11-07 SG SG10201704687YA patent/SG10201704687YA/en unknown
- 2013-11-07 JP JP2014545578A patent/JP6254529B2/ja active Active
- 2013-11-07 BR BR112015010428A patent/BR112015010428B1/pt active IP Right Grant
- 2013-11-07 AU AU2013342882A patent/AU2013342882B2/en active Active
- 2013-11-07 SG SG11201503612QA patent/SG11201503612QA/en unknown
- 2013-11-07 WO PCT/JP2013/006563 patent/WO2014073209A1/ja active Application Filing
- 2013-11-07 MX MX2015005842A patent/MX363111B/es unknown
- 2013-11-07 KR KR1020157013042A patent/KR102173932B1/ko active IP Right Grant
- 2013-11-07 NZ NZ708756A patent/NZ708756A/en unknown
- 2013-11-07 US US14/440,832 patent/US9492431B2/en active Active
2015
- 2015-05-07 CL CL2015001225A patent/CL2015001225A1/es unknown
- 2015-05-08 MX MX2019002526A patent/MX2019002526A/es active IP Right Grant
- 2015-06-05 ZA ZA2015/04065A patent/ZA201504065B/en unknown
2016
- 2016-06-22 HK HK16107218.3A patent/HK1219224A1/zh unknown
- 2016-10-14 US US15/293,548 patent/US9750721B2/en active Active
2017
- 2017-07-20 US US15/655,418 patent/US10016395B2/en active Active
- 2017-11-30 JP JP2017230426A patent/JP6462836B2/ja active Active
2018
- 2018-06-14 US US16/008,730 patent/US10537556B2/en active Active
- 2018-07-13 CL CL2018001915A patent/CL2018001915A1/es unknown
- 2018-08-13 AU AU2018217197A patent/AU2018217197B2/en active Active
- 2018-12-27 JP JP2018244364A patent/JP6744389B2/ja active Active
2019
- 2019-12-02 US US16/700,866 patent/US11471440B2/en active Active
2022
- 2022-09-07 US US17/939,198 patent/US20230255937A1/en active Pending

Also Published As

Publication number	Publication date
AU2013342882A1 (en)	2015-06-11
US9492431B2 (en)	2016-11-15
CL2015001225A1 (es)	2016-03-04
NZ708756A (en)	2019-07-26
JPWO2014073209A1 (ja)	2016-09-08
AU2013342882B2 (en)	2018-05-17
RU2015121628A (ru)	2016-12-27
MX363111B (es)	2019-03-08
CN109589324A (zh)	2019-04-09
EP2918290B1 (en)	2020-09-02
BR112015010428A2 (pt)	2017-07-11
EP2918290A4 (en)	2016-05-18
US20180000782A1 (en)	2018-01-04
JP2019069992A (ja)	2019-05-09
CN105188753A (zh)	2015-12-23
JP6462836B2 (ja)	2019-01-30
WO2014073209A1 (ja)	2014-05-15
MX2019002526A (es)	2019-07-15
KR102173932B1 (ko)	2020-11-04
US20190134002A1 (en)	2019-05-09
BR112015010428B1 (pt)	2020-04-22
US10537556B2 (en)	2020-01-21
CA2890424C (en)	2020-11-17
AU2018217197A1 (en)	2018-08-30
US20200345695A1 (en)	2020-11-05
AU2018217197B2 (en)	2020-03-05
CN105188753B (zh)	2018-12-18
JP2018030887A (ja)	2018-03-01
SG10201704687YA (en)	2017-07-28
US20230255937A1 (en)	2023-08-17
CL2018001915A1 (es)	2018-08-31
US9750721B2 (en)	2017-09-05
EP2918290A1 (en)	2015-09-16
JP6254529B2 (ja)	2017-12-27
US20170065562A1 (en)	2017-03-09
SG11201503612QA (en)	2015-06-29
RU2659203C2 (ru)	2018-06-28
CA2890424A1 (en)	2014-05-15
ZA201504065B (en)	2016-11-30
US20150290172A1 (en)	2015-10-15
CN109589324B (zh)	2022-06-14
US10016395B2 (en)	2018-07-10
MX2015005842A (es)	2016-01-20
KR20150082326A (ko)	2015-07-15
US11471440B2 (en)	2022-10-18
JP6744389B2 (ja)	2020-08-19
ES2834111T3 (es)	2021-06-16

Publication	Publication Date	Title
HK1203963A1 (zh)	2015-11-06	新型治療藥物
GB201212513D0 (en)	2012-08-29	Therapeutic agents
HK1206297A1 (zh)	2016-01-08	用於聯合療法的藥物組合物
HK1206620A1 (zh)	2016-01-15	血脂異常症治療劑
HRP20190050T1 (hr)	2019-03-08	Farmaceutski pripravci za kombinacijsku terapiju
GB201217704D0 (en)	2012-11-14	Therapeutic agents
HK1201209A1 (zh)	2015-08-28	糖尿病的治療藥
PL2723330T3 (pl)	2015-12-31	Lek kombinowany zawierający środek naczynioskurczowy
HK1219224A1 (zh)	2017-03-31	角結膜病症的治療劑
PT2861242T (pt)	2018-11-07	Disfunções relacionadas com o glúten
GB201420971D0 (en)	2015-01-07	Therapeutic composition
EP2804853A4 (en)	2015-09-23	THERAPEUTIC USES
GB201223021D0 (en)	2013-02-06	Therapeutic agents
GB201212512D0 (en)	2012-08-29	Therapeutic agents
GB201210233D0 (en)	2012-07-25	Therapeutic agents
ZA201405764B (en)	2017-09-27	Novel therapeutic agents
IL236873A0 (en)	2015-03-31	therapeutic compounds
GB201214985D0 (en)	2012-10-03	Modified therapeutic agents
GB201213712D0 (en)	2012-09-12	Modified therapeutic agents
GB201213192D0 (en)	2012-09-05	Support for therapeutic
GB201211528D0 (en)	2012-08-08	Therapeutic apparatus
GB201202918D0 (en)	2012-04-04	Therapeutic device
HUE043019T2 (hu)	2019-07-29	Gyógyszerészeti készítmények kombinációs terápia céljára
GB201101128D0 (en)	2011-03-09	Therapeutic agents